Biodexa Pharmaceuticals (BDRX) Current Assets (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Current Assets across 13 years of filings, most recently posting $16.6 million for Q4 2025.

• In Q4 2025, Current Assets rose 46.37% year-over-year to $16.6 million; the TTM figure through Dec 2025 stood at $16.6 million (up 46.37% YoY), while the FY2025 annual figure was $16.4 million, up 45.68% from the prior year.
• Current Assets came in at $16.6 million for Q4 2025 at Biodexa Pharmaceuticals, up from $12.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $16.6 million in Q4 2025 to a low of $5.5 million in Q4 2022.
• Average Current Assets over 5 years is $10.9 million, with a median of $10.4 million recorded in 2021.
• Year-over-year, Current Assets plunged 65.32% in 2022 and soared 58.68% in 2023.
• Over 5 years, Current Assets stood at $15.9 million in 2021, then sank by 65.32% to $5.5 million in 2022, then surged by 58.68% to $8.7 million in 2023, then climbed by 29.6% to $11.3 million in 2024, then surged by 46.37% to $16.6 million in 2025.
• Per Business Quant data, the three most recent Current Assets figures were $16.6 million in Q4 2025, $12.0 million in Q2 2025, and $11.3 million in Q4 2024.